Femme et Homme
- | Pays :
- Poland
- France
- Netherlands
- | Organes : -
- | Spécialités : -
Extrait
This 2-part, randomized, double-blind, placebo-controlled study will assess the safety, pharmacokinetics and pharmacodynamics of RO5428029 in healthy volunteers and patients with hepatitis C infection. Cohorts will be randomized to receive either RO5428029 in ascending doses or placebo for up to 7 days (patients) or up to 14 days (healthy volunteers).
Critère d'inclusion
- Hepatitis C, Chronic, Healthy Volunteer